Compare · COO vs RXST
COO vs RXST
Side-by-side comparison of The Cooper Companies Inc. (COO) and RxSight Inc. (RXST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COO and RXST operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- COO is the larger of the two at $19.03B, about 98.0x RXST ($194.2M).
- COO has been more active in the news (6 items in the past 4 weeks vs 1 for RXST).
- Both have 25 recent analyst ratings on file.
- Company
- The Cooper Companies Inc.
- RxSight Inc.
- Price
- -
- -
- Market cap
- $19.03B
- $194.2M
- 1M return
- -
- -15.15%
- 1Y return
- -
- -45.30%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 1
- Recent ratings
- 25
- 25
The Cooper Companies Inc.
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.
RxSight Inc.
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
Latest COO
- Barclays initiated coverage on Cooper with a new price target
- New CooperVision® Consumer Insights Report Reveals Multifocal Contact Lenses Are Viewed as a Leading Anti-Aging Solution
- Seneca Polytechnic and CooperVision Canada open Contact Lens Centre of Excellence to help advance the future of vision care
- COOPER COMPANIES, INC. COO INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 14.7% Share Drop
- CooperCompanies Unveils Accelerated CooperVision Innovation Strategy at The Vision Centre Opening
- CooperVision Powers the Next Era of Eye Care with New Global Vision Centre and Major Pipeline Advancements
- JANA Partners Sends Letter to Cooper Board of Directors
- Director Kurzius Lawrence Erik bought $549,320 worth of shares (10,000 units at $54.93), increasing direct ownership by 47% to 31,099 units (SEC Form 4)
- Director Rosebrough Walter M Jr bought $541,640 worth of shares (10,000 units at $54.16) (SEC Form 4)
- Director Kurzius Lawrence Erik bought $539,150 worth of shares (10,000 units at $53.91), increasing direct ownership by 90% to 21,099 units (SEC Form 4)
Latest RXST
- K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world
- Officer Weinberg Eric exercised 35,168 shares at a strike of $4.34, increasing direct ownership by 18% to 235,516 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Wilterding Mark
- SEC Form 4 filed by Officer Weinberg Eric
- SEC Form 4 filed by Chief Medical Officer Kurtz Ronald M Md
- SEC Form 4 filed by Chief Operating Officer Goldshleger Ilya
- Amendment: SEC Form SC TO-I/A filed by RxSight Inc.
- Chief Medical Officer Kurtz Ronald M Md converted options into 13,425 shares and sold $35,496 worth of shares (5,100 units at $6.96), increasing direct ownership by 13% to 71,775 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Wilterding Mark converted options into 20,441 shares and sold $54,044 worth of shares (7,765 units at $6.96), increasing direct ownership by 102% to 25,049 units (SEC Form 4) (tax withholding)
- Chief Operating Officer Goldshleger Ilya converted options into 5,370 shares and sold $14,205 worth of shares (2,041 units at $6.96), increasing direct ownership by 4% to 81,509 units (SEC Form 4) (tax withholding)